AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

The Main Street Pharmacy Access Act/Ensuring Community Access to Pharmacist Services Act (H.R. 3164/S. 2426), including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation). Issues related to extension of site-neutral policies to drug administration services in hospital provider-based departments (generally, no specific legislation). Issues related to implementation of Medicare drug price negotiation (generally, no specific legislation). Issues related to removal of administrative barriers to pharmacist services in Medicare Advantage (generally, no specific legislation). Issues related to CMS proposed rules, including the inpatient prospective payment system (IPPS) proposed rule, the proposed rule on interoperability and prior authorization (PA) for drugs, the outpatient prospective payment system (OPPS) proposed rule, and the physician fee schedule (PFS) proposed rule.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 3164

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 3269

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 3514

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R.3789

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 4122

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 4581

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 5526

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 5880

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 6485

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 7184

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 7994

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 8005

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 8646

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 929

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 9396

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 9599

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: H.R. 9661

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: S. 1087

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: S. 1954

The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.

Client expense: $250,000 · Firm income: —

Matched citations: S. 2372

The Main Street Pharmacy Access Act/Ensuring Community Access to Pharmacist Services Act (H.R. 3164/S. 2426), including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation). Issues related to extension of site-neutral policies to drug administration services in hospital provider-based departments (generally, no specific legislation). Issues related to implementation of Medicare drug price negotiation (generally, no specific legislation). Issues related to removal of administrative barriers to pharmacist services in Medicare Advantage (generally, no specific legislation). Issues related to CMS proposed rules, including the inpatient prospective payment system (IPPS) proposed rule, the proposed rule on interoperability and prior authorization (PA) for drugs, the outpatient prospective payment system (OPPS) proposed rule, and the physician fee schedule (PFS) proposed rule.

Client expense: $250,000 · Firm income: —

Matched citations: S. 2426